Form 4: Oric Pharmaceuticals CFO Sells Shares Under Pre-Arranged Trading Plan

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, reported the sale of 300 shares of common stock for $10 per share, executed under a pre-established 10b5-1 trading plan.

Summary

• Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (ORIC), reported a transaction involving the company's common stock.
• He disposed of 300 shares of common stock on June 12, 2025, at a price of $10 per share.
• Following this sale, Mr. Piscitelli directly beneficially owns 101,817 shares of Oric Pharmaceuticals common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Piscitelli on December 30, 2024.

Sentiment

Score: 5

Explanation: A neutral score. The transaction is a sale by an insider, which can sometimes be viewed negatively, but it was conducted under a pre-arranged 10b5-1 plan, indicating it was not based on new, non-public information, making it a routine and expected event.

Future Outlook

NA

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide broader industry context or trends. It is specific to Oric Pharmaceuticals and its Chief Financial Officer.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by a key executive, while routine under a 10b5-1 plan, could be observed by investors as a minor reduction in insider ownership, though its impact is likely minimal given the pre-planned nature and small volume.

Key Dates

Keywords

Oric Pharmaceuticals, ORIC, Dominic Piscitelli, CFO, Insider Trading, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan, Common Stock